The International Generic and Biosimilar medicines Association (IGBA), which represents global manufacturers of generic and biosimilar medicines, today requests urgent action by all governments to designate all medicines as PRIORITY ESSENTIAL PRODUCTS, including all critical goods needed to manufacture them, so as to ensure that patients around the globe can continue to access the medicines they need during the COVID-19 pandemic.
The current operating model of medicines supply requires transparent global collaboration to provide access to medicines for patients around the world.
The International Generic and Biosimilar medicines Association (IGBA), which represents global manufacturers of generic and biosimilar medicines, today requested urgent action by governments and pharmaceutical supply chain stakeholders to reopen air freight routes and ensure patients around the globe can continue to have access to the medicines they need during the COVID-19 pandemic.
- COVID-19: Critical to keep the supply chain of essential medicines manufacturing operating at full capacity (18 March 2020)
- Hanan Sboul takes over the position of IGBA Chair (January 2020)
- IGBA applauds long-awaited scientific harmonization process of bioequivalence studies (December 2019)
- IGBA Statement on Hosting of Pat-INFORMED by WIPO (December 2019)
